Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4IAKR)

Drug Name
MD-1100 Drug Info
Synonyms Linaclotide acetate; Linaclotide acetate (USAN); MM-416775
Indication
Disease Entry ICD 11 Status REF
Constipation DD91.1 Approved [1]
Irritable bowel syndrome DD91.0 Phase 2 [2]
Cross-matching ID
PubChem CID
16158207
CAS Number
CAS 851199-60-5
TTD Drug ID
DM4IAKR

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Guanylyl cyclase C (GUCY2C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Linaclotide DM4EGV0 Irritable bowel syndrome DD91.0 Approved [3]
Plecanatide DMKEX7O Chronic idiopathic constipation DC32 Approved [4]
SP-333 DM2UKJV Ulcerative colitis DD71 Phase 2 [5]
MLN0264 DMI4E9K Gastrointestinal cancer 2C11 Phase 2 [6]
PF-07062119 DME3BJL Solid tumour/cancer 2A00-2F9Z Phase 1 [7]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Guanylyl cyclase C (GUCY2C) TTLDPRG GUC2C_HUMAN Activator [2]

References

1 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
2 Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
3 Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 J Clin Oncol 31, 2013 (suppl; abstr TPS3646).
7 Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors. MAbs. Jan-Dec 2021;13(1):1850395.